Maureen Hoatlin

Current

• Associate Professor Biochemistry and Molecular Biology at Oregon Health and Science University

Past

• Assistant Professor, Biochemistry & Molecular Biology and Molecular Medicine at Oregon Health and Science University
• Research Assistant Professor at Oregon Health and Science University
• Pasman Visiting Scientist & Professor, Department of Genetics at Vrije Universiteit Amsterdam

• Research Associate at Genentech Inc.
• Research Associate at SRI International

see less...

2 more...

Education

• Oregon Health and Science University School of Medicine
• Old Dominion University

Connections

257 connections

Industry

Research

Websites

• Hoatlin Lab Website
• My Webpage

Maureen Hoatlin’s Summary

Principal Scientist, Discovery Research

Discovery and analysis of novel proteins that control cancer susceptibility. Special focus on the protein network defective in Fanconi anemia, a genetic disorder leading to bone marrow failure, hematologic malignancy and other cancers. Experience in biotechnology industry and academic settings

Maureen Hoatlin’s Specialties:

Recruiting and motivating team of scientists; multi-site matrixed collaborations; translational applications of molecular biology including vaccines, specialized antibodies and novel cell-free screens for small molecule inhibitors; science education 2.0 and outreach; user and enthusiastic supporter of OpenWetWare (www.openwetware.org)

Maureen Hoatlin’s Experience

• Associate Professor Biochemistry and Molecular Biology

  Oregon Health and Science University

  (Educational Institution; Research industry)

  June 2008 — Present (1 year 2 months)

  Group leader of laboratory identifying and analyzing novel DNA damage response proteins by using human cell-based assays and novel assays for drug discovery
  
  • Created unique antibodies and established collaborations resulting in co-discovery and characterization of six novel human cancer susceptibility genes
  • Discovered a novel human gene resulting in a improved understanding of the regulation of early hematopoiesis
  • Pioneered use of a cell-free system and developed a novel small molecule inhibitor screen for a protein network that modulates human bone marrow failure and cancer susceptibility leading to identification of several potential chemosensitizing compounds
  • Developed an independent research program and leveraged small startup to obtain competitive funding resulting in awards totaling $5M
  • Three patent applications on two technology inventions; three biomaterials licenses for nine biomaterial inventions on cancer-related screening methods and drug discovery

• Assistant Professor, Biochemistry & Molecular Biology and Molecular Medicine

  Oregon Health and Science University

  (Research industry)

  2000 — 2008 (8 years)

• Research Assistant Professor

  Oregon Health and Science University

  (Research industry)

  1993 — 1999 (6 years)

• Pasman Visiting Scientist & Professor, Department of Genetics

  Vrije Universiteit Amsterdam

  (Educational Institution; 1001-5000 employees; Research industry)

  April 1998 — January 1999 (10 months)

  Fellowships (1998 & 4/2002-6/2002) to establish collaborative activities between OHSU and the Genetics/Oncology Departments at the Free University of Amsterdam and Medical Center and to advance joint research on Fanconi anemia.
  
  • Created retroviral expression vectors and high-titer viruses resulting in more accurate and faster identification of gene-specific defects in Fanconi patient cell lines
  • Created a panel of antibodies that contributed to discovery and characterization of new genes associated with the Fanconi anemia/Breast Cancer Pathway and insights into the cell biology of a novel arm of the human cancer susceptibility protein network.

• Research Associate

  Genentech Inc.

  (Public Company; Research industry)

  1981 — 1987 (6 years)

  Laboratory of Dennis Kleid Ph.D.
  Cloning and expression of proteins of clinical significance including immunogenic regions of foot-and-mouth disease virus, rabies virus, poliovirus and HIV.
  
  • Led project to develop neutralizing antibodies for subunit vaccine technology for poliovirus extending the use of subunit vaccine methodology to new therapeutic targets
  • Preclinical research for recombinant subunit vaccines for two different viruses, representing a new advance in anti-viral technology

• Research Associate

  SRI International

  (Non-Profit; 1001-5000 employees; Research industry)

  1979 — 1981 (2 years)

  Analysis of novel nucleoside analogs with anti-cancer properties for the National Cancer Institute by physical and chemical analysis using mass spectrometry, NMR, atomic absorption, gas and liquid chromatography, and infrared spectrometry.

Additional Information

Maureen Hoatlin’s Websites:

• Hoatlin Lab Website
• My Webpage

Maureen Hoatlin’s Interests:

Interested in strategies to foster productive collaborative science, enduring interest in vaccine development, computers, instrumentation and gadgets, emerging interest in synthetic biology

Maureen Hoatlin’s Groups:

OpenWetWare
American Association for Cancer Research
American Society of Hematology
American Society of Microbiology
Women in Cancer Research

•    Genentech Employees and Alumni
•    San Diego Science Festival (SDSF)
•    OpenWetWare
•    SRI Connect
•    Grant Review Group for WICR Members

Maureen Hoatlin’s Honors:

OHSU Biosciences Innovation Fund Award,Technology Innovation Award, Three Awards for Gene Discovery from the Fanconi Anemia Research Fund, Visiting Professor Fellowship from the Free University of Amsterdam, Visiting Scientist Fellowship from the Free University of Amsterdam, NIH-NIMH Board of Scientific Counselors, NIH FIRST Award, Scientist Development Award from the American Heart Association, Recognition Award, Genentech, Inc.

Maureen Hoatlin’s Contact Settings

Interested In:

• career opportunities
• consulting offers
• new ventures
• job inquiries
• expertise requests
• business deals
• reference requests
• getting back in touch